Shattuck Labs, Inc.

Healthcare · Biotechnology · United States

Last price 5.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 574.08M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical...